[]
|
|
07-04-23 15:06
13,022
|
.(Whole blood, WB)̶ Դϱ?
45 Ǵ 56 mL CPDA-1 ִ bag 320 Ǵ 400 mL
äϿ Դϴ. 츶ũƮ 밳 36-40% ̸ ä
24ð ̿ Ǿ ִ Ȱ Ҿ factor V
VIII Ȱ Ҿ ˴ϴ. ݵ 1-6 C ؾ ϸ, Ⱓ 35
Դϴ. ǿ¿ 30 ̻ ʽϴ. ä 24ð ̳ ż
(fresh whole blood) 缺 ABO Rh
typing, AIDS ˻ ˻縦 ϴµ ҿǴ ð ϸ ˻
ż Ⱑ Ұմϴ. ä Ⱓ 7 ̳
2,3-DPG ǰ Ƿ Ż ȯ ġḦ ȯ
ϰ ֽϴ.
쿡 ˴ϱ?
ִ ȯ, 25% ̻ Ǵ ӵǾ ũ ִ ȯڿԴ ϴ ϴ. ҿݴɰ Ȯ ÿ 䱸 ϴ ˴ϴ. Ǵ ȯڿ Լӵ ϸ ϸ ʷϿ Ƿ ؾ մϴ. 24ð ̻ ǰ factor V VIII ϵǾ ֽϴ. ǰ ϱ ؼ Ǵ ؾ ϸ ڸ ϱ ؼ ż (fresh frozen plasma) ؾ մϴ.
Դϱ?
ǰ ֽϴ. 뷮 ϴ. 游 ʿ ϴ ȯڿ ־ ˴ϴ. ҿݴ ȯڿԴ ϴ ǽϴ. ϱ ȯڿ ´ ݵ ȮϿ մϴ. ABO ʴ ϸ ۿ ߵǹǷ Ͽ մϴ. Ǿ ִ ߿ ߵ , AIDS ļ ȯ ɼ ϴ.
ؾ մϱ?
1 ϸ ۷κ 1 g/dL ϰ, 츶ũƮ 3-4% մϴ. Ҿ ۷κ 1g/dL Ű ؼ 8 mL/kg ʿմϴ. ݵ Ͱ ִ Ʈ ؼ Ͽ մϴ. ӵ ȯ ӻ ¿ Ͽ ϸ 1 ִµ 4ð ʰ ʵ ؾ մϴ.
.(Red Blood Cells, RBCs) Դϱ?
κ ɺи 160-200 mL 强а Ǽ մϴ. 츶ũƮ 70% Ǹ ϰ ֽϴ. ϹǷ ҿݴ ֽϴ. 1-6 C մϴ. Ⱓ 35Դϴ.
쿡 ˴ϱ?
ҿݴ ̴ ȯ Ǵ ܻ 15% ̻ ִ ȯ ġῡ ̿˴ϴ. ź̳ Ǽ ȯڵ ̹Ƿ ϸ ֽϴ. ۷κġ 8 g/dL ̻ 쿡 ʿ 찡 ϴ. ̳ ܻ 15% ̸ ÿ κ ʿմϴ. մϴ.
*
(γ) = ü(kg) x 68 mL
(ο) = ü(kg) x 62 mL
Դϱ?
쿡 ۿ ʷ , (Hypervolemia) ų ֽϴ.
ؾ մϱ?
ݵ Ͱ ִ Ʈ ؾ մϴ. 츶ũƮ Ǿ ־ ӵ ϴ. 50-100 mL Ŀ(0.9% NaCl) Ͽ ҽŲ Ͽ մϴ. ȥ ִ Ŀۿ ؾ մϴ. ã ƴٰ ؼ 5% Ǵ Ʈ װ Բ ϸ Ǵ κ ɰ ۿ ʷ Ƿ Ͽ մϴ.
. (Leukocyte-depleted Blood Components) Դϱ?
109, 108-109, ǿ 107-108, äǿ 106-108 Ǵ Ǿ ֽϴ. ߿ ۿ ų ֽϴ. HLA 鿪 ߵǾ Ǽ (platelet refractoriness) ų ֽϴ. cytomegalovirus(CMV) ̷ ϹǷ ̷ ü ۿ Ƿ 鿪 Ǿ ִ ȯڿ CMV ̷ ֽϴ. ߿ ۿ Ϸ Ǿ ִ 5 x 108 Ϸ ٿ ϰ HLA 鿪 ϱ ؼ 5 x 106 Ϸ ҽѾ մϴ. ϴ ߿ ȿ ϴ Դϴ. ϸ 99.9% ̻ ֽϴ.
쿡 ˴ϱ?
1) ߿ ۿ
2) HLA 鿪
Ǵ , ҷ Ǵ ġÿ ó ݵ Ͽ 鿪 ֽϴ.
3) CMV ̷
鿪 ϰ ִ ̽ ȯ Ǵ 鿪 ϵ ȯ ˴ϴ.
.(Platelet Concentrates)̶ Դϱ?
κ Ǹ 50 mL ӿ 5 X 1010 ֽϴ. õõ ִ ġ ϸ µ 20-24CԴϴ. Ϲ 3ϰ ϸ 5ϰ ֽϴ.
쿡 ˴ϱ?
Ǵ Դϴ. Ǵ ְ ִ ȯڿ ȸŰ ˴ϴ. Ǵ ҷ , ġ, Ǽ ħ, Ͽ Ǽ 20,000/L Ϸ ҵ ȯڵ鿡 ַ ˴ϴ.
Դϱ?
Ǽ ڰ鿪 Ҽ ڹ(ITP) (DIC) Ͽ ı Ͼ ȯڿԴ 밳 ȿ ϴ. Ǵ ε ǰ ȯڿԵ Ǽ ʽϴ. ۿ , ߿ ˷⼺ Ͼ ֽϴ. ߿ÿ ƽǸ ؿ Ǵµ ƽǸ cyclooxygenase Ȱȭ Ű Դϴ. ӿ ҷ Ƿ Rh ȯڿԴ ݵ Rh Ͽ մϴ. ӿ ȯڿ Rh 缺 Ұ Rh 鿪 ϱ Ͽ ݵ Rh 鿪۷κҸ(Rhogam) ؾ մϴ
ؾ մϱ?
1 ϸ Ǽ 5,000/L ̻ ˴ϴ. ǰ 6-10 ϸ Ҿ ü 10 kg 1 մϴ. (DIC), , , ü , Ǵ ġÿ Ǽ ɴϴ. 1ð Ŀ Ǽ ʴ HLA 鿪 ɼ ϴ. CCI (corrected count increment) θ ֽϴ.
Ǽ - Ǽ
CCI = ----------------------------------------------- x üǥ(m2)
Ǽ x 1011
1ð Ŀ CCI 7.5 x 109/L ̸̰ų 18-24 ð CCI 4.5 x 109/L ̸ ǹմϴ. ݵ Ͱ ִ Ʈ Ͽ Ǿ մϴ.
.ä(Apheresis platelets)̶ Դϱ?
ä(plateletpheresis) ä⸦ ̿Ͽ ڷκ Ǹ äϴ 밳 2-3ð ҿǸ ̷κ ä ̶ մϴ. 6-8 شϴ 3 X 1011 差 200-250 mL Դϴ. ä 6-8 ڷκ ִ ǿ شǴ 1 ڷκ Ƿ ȯڿ Ǵ ٿ ŭ HLA 鿪 ȸ ְ ļ ȯ ȸ ִ ֽϴ.
쿡 ˴ϱ?
ǰ ϴ.
.ż(Fresh frozen plasma, FFP)
ż κ ä 6ð ̳ и Ų μ Ҿ V VIII ڸ ڸ ϰ ־ ϴ ߿ Դϴ. ż 뷮 Ͽ ϴ ϳ λϿٴ ָ Դϴ. ż 뷮 ڸ ȯڰ þ ε ƴ϶ 뿡 ִ мǾϴ. ϴ Snyder м ̰ ż ȥϿ ϴ ʵ ־ٰ ϸ żdz Ͽϴ. 1984 ̱ National Institutes of Health (NIH) Consensus Conference ̱ǽż 10⵿ 10 Ͽ ֽϸ鼭 Ȯ (definitive indication) ұϰ, ȿ̸ ٸ ġ ұϰ ǰ ִ ̹Ƿ ǥ ֽϴ.
1) Ȯ (volume expander) ؼ ȵȴ.
2) (crystalloid) Ǵ ˺ι, Hydroxyethyl starch (HES), Dextran
(colloid fluid) ϰ ̴.
3) 纸 Ͽ ؼ ȵȴ.
(hyperalimentation) Ǵ Dextrose ϴ .
4) ̵ ̴.
츮 ż 뷮 1987 1992 5 ̿ 5 Ȯ Ÿ缺 Ῡ 뵵 ǰ ִ Դϴ. ż B C , õ 鿪 (AIDS) ļ ȯ ߺ ɼ ų ƴ϶ ˺ι Ǵ VIII ʷϰ ֽϴ. ˺ι μ ܱ ϰ ִ 츮 Դϴ. ż ϸ Ǿ ִ, ùٸ , ùٸ , ۿ뿡 ִ ڽϴ.
ż
ż CPDA-1 ִ 鿡 400 Ǵ 320 mL äϿ ä 6ð ̳ 4ɿ 5000 g 5 ɺи и -18 Ͽ õϿ մϴ. õ ȿⰣ 1Դϴ. ż ݰⰡ ª Ҿ V VIII ڸ ڸ ϰ ֽϴ. 츮 Ǵ ż տ뷮 160-180 mL ̸ I ҿ (fibrinogen) 230-240 mg/dL, V ڴ 119 U/dL, VII ڴ 89-94 U/dL, 캴 VIII ڴ 49-94 U/dL, IX ڴ 84-125 U/dL Ǿ ֽϴ. ż ϴµ ż ü ǥ 1 ϴ.
ǥ 1. ü
ݰ ȸ 4
I (Fibrinogen) 100 mg/dL 4-6 days 50%
II 40% 2-3 days 40-80%
V 10-15% 12 hours 80% Ҿ
VII 5-10% 2-6 hours 70-80%
VIII 10-40% 8-12 hours 60-80% Ҿ
IX 10-40% 18-24 hours 40-50%
X 10-15% 2 days 50%
XI 30% 3 days 90-100%
XII - - -
XIII 1-5% 6-10 days 5-100%
(, , ѱԼ. . 1993. p 50)
ż ص ϸ 밳 37 ̿ϰ ֽϴ. ֱٿ 37 صð ª ż ʿ信 ص ż տ ɼ microwave oven ̿ ص Ұ ֽϴ. 1ȸ صų ִ ż 3 ѵǴ ֽϴ.
ż ܹ ϰ ֱ VIII, ҿ, von Willebrand factor, fibronectin fibrin glue dzϰ ϰ ִ ħ (cryoprecipitates) VIII (factor VIII concentrates), IX (prothrombin complex), 鿪۷κҸ ˺ι ȹ (plasma derivatives) ε ϰ ˴ϴ.
ż ùٸ
ż ùٸ ʽϴ. ż , AIDS ļ ȯ ȸ ڿ ȹ ظ ʷ ֱ ݵ ùٸ ܿ ʴ ǰ ֽϴ. Ͽ ż Ȯ Ÿ缺 Ῡ ǰ ִ Դϴ. NIH Consensus Conference Ÿ缺 Ǵ , 汸 ȿ , 뷮, ƮҺ III , ǰҼ ڹ (thrombotic thrombocytopenic purpura, TTP) Ͽϴ. 鵵 ż常 ġ ƴ 쵵 ֽϴ. ż ؼ ڼ 䰡 ʿմϴ.
Ÿ缺 Ǵ
1)
VIII IX ϸ ڰ ̵ 年ϴ. VIII (캴 A) ħ Ǵ VIII ڸ ϴ Դϴ. IX (캴 B)ÿ IX ڸ ϴ ּԴϴ. ҿ ̵ ȯڿԴ ħ (cryoprecipitates) ؾ ϸ von Willebrand ȯڿԴ ż ʿϸ 1-desamino-8-D-arginine vasopressin (DDAVP) Ҿ VIII ڸ ϴ ϴ. ż ּ ̵ 쿡 Ǹ V ֽϴ.
2) 汸 ȿ
Warfarin (Coumadin) bishydroxycoumarin (dicumarol) coumarin 汸 ȯڵ Ÿ K- ܹ II, VII, IX, X protein C, protein S Ȱ Ǿ ֽϴ. Coumarin Ÿ K- ܹ gamma-carboxylation Ͽ ۿ Ÿϴ. 汸 忡 Ǿ ƮҺ ð (PT) ŵϴ. ݰⰡ 2.5 ȿ Ÿ 뷮 պ ֽϴ. ϸ coumarin ϰ Ÿ K Ͽ ϸ 밳 6-12ð ǰ PT ȭ ֽϴ. coumarin ȿ żϰ Ű ؼ prothrombin complex Ǵ ż ؾ մϴ.
3) Ÿ K
Ż ȯ, 㵵 Ÿ K ָ ϴ ȯ鿡 汸 ÿ ְ Ÿ ˴ϴ. ̷ ȯڵ鿡 Ÿ 汸 óؾ մϴ.
4) (DIC)
, ܻ, ݵ ִ (disseminated intravascular coagulopathy, DIC)ÿ ر Բ ȰȭǾ ҵǰ Ǵ ֽϴ. DIC ʷ ȯ ġᰡ Ǿ ϸ ݵ DIC ż, ħ, ֽϴ. DIC 쳪 ݵ 쿡 ˻Ұ ̶ ǽ ʴ Դϴ.
5) ǰҼ ڹ (TTP)
ǰҼ ڹ (thrombotic thrombocytopenic purpura, TTP) , ̼ (microangiopathic) , ߿, Ű , ű ̻ Ư¡ ϴ ȯ ż ϴ ġ 屳ȯ (therapeutic plasmapheresis) ּ ġ Դϴ. 80% ȯڿ ż 屳ȯ ȿ ־ٴ ֽϴ. ż Ǵ ħ-(cryoprecipitate-depleted) ġ ȿ ִ Ȯġ TTP ȯڿ VIII ü (factor VIII:vWF) ϴ ڷ ſ ū multimeric von Willebrand factor óϴ depolymerase ֱ ̶ մϴ.
6)
ƮҺ III, protein C, protein S ̵ ȯڵ ް Ǵ 쳪 ġ ĸ ް Ǵ ż ʿմϴ. C1 esterase ÿ ż ֽϴ.
ؾ ϴ
1) 뷮 (Massive transfusion)
뷮 24ð ȯ ̻ ϴ ǵǾ ֽϴ. NIH Consensus Conference 뷮 ż Ͱ ־ 뷮 ȯڵ鿡 ǰ ε 찡 Ȯ ż ϴ Ÿ缺 ٰ Ͽϴ. 뷮 ڰ DZ Ÿ ִ ġ ʽϴ. 뷮 ִ κ а, , ְ ִ ȯڵ鿡 DIC պʿ ڰ ҸǾ ߵ˴ϴ. 뷮 ϴ Ǽ, ҿ, PT, aPTT ˻縦 ÷ Ͽ 뷮 ȯڿ ǰ (50,000/uL ) ε ̿ ε Ǵ ϴ Դϴ. ҿ 80 mg/dL ̸ ħ ϰ ҿ 80 mg/dL ̸̻鼭 PT, aPTT 1.5 ̻ Ǿ V ڿ VIII ǹϹǷ ż Ͽ մϴ. ż ô ּ 4 ̻ ؾ ȿ ֽϴ.
2) ȯ
ȯ ż ǰ ֽϴ. ȯ ȯڿ II, V, VII, IX, X ռ , Ȱ ûҷ (clearance) ο Ͽ ְ ĵ Ʒ պ ߵ Ƿ ݵ ֽϴ. ְų , Ȯ Ǵ 쿡 ż dz PT, aPTT Ұ߸ ż ϴ ٶ մϴ. PT, aPTT ɼ ϸ ż ȯ ȯڿ PT, aPTT ϴ ͵ Դϴ. ȯ ȯڿ PT, aPTT Ǿ ϴ ż Ÿ缺 ϴ. 6-8 ż Ͽ ʰ PT 쿡 prothrombin complex Ͽ մϴ.
3) ȸ
ȸ (cardiopulmonary bypass surgery) κ ȯڵ ָ ȸ ߿ ȭ Ͼ ˴ϴ. ȸ ̴ κ ̺ٴ Դϴ. ִ 밳 ȸμ 1ð ̳ ȭ˴ϴ. ̼ ̳ 켱 ϴ ϴ. ż ˻ 쿡 մϴ. ż ϴ ǹ̰ ȯڿ ļ ȯ ɼ ̰ ˴ϴ.
ż Ÿ ʴ
1) (Hypovolemia)
NIH Consensus Conference ֵ Ȯ Ͽ ż ϴ Ÿ缺 ϴ. (crystalloids), ռ (synthetic colloids), ˺ι ϰ ̸ 뵵 մϴ.
2) () (Formula replacement)
4-6 ø 1 ż ϴ ﰡ մϴ. ̴ ȯڿ ļ ȯ ɼ ٸ Դϴ.
3) ܹ (protein-losing states)
纸 ̳ (ascites) ȭ, , ܹǼ (protein-losing enteropathy), (thoracic duct drainage) ܹ Ϸ ż ؼ ȵ˴ϴ.
4) 鿪 ġ
鿪 ȯڿ 鿪۷κҸ ϱ ؼ ż ϴ ͺ 鿪۷κҸ ϴ ϴ.
ż ùٸ
ż ȯ ӻ ¿ ٸϴ. 뷮 ȯ ϴ Բ Ͽ 뷫 ִµ ̳ Ҿƿ 밳 10 mL/kg ϸ ǰ 15 mL/kg 뷮 ϴ ϹԴϴ. ȯ ¸ PT, aPTT Ǵ ˻ϴ ߿մϴ. ż嵵 Ͱ ִ Ʈ Ͽ Ͽ մϴ. ż ص ؾ մϴ. 1-6ɿ Ͽ ϸ ʾ 24ð ̳ Ǿ մϴ. ʿϸ ABO ż ϸ ˴ϴ.
ż ۿ
1. (Volume overload)
ż ϰ ϸ ż ʿϹǷ ϰ Ͼ ߵ ֽϴ. ϸ ħ Ǵ ̵ ϴ ϴ.
2. ˷ (Allergic reactions)
ż ȯ 1-3% ε巯Ⱑ Ÿϴ. IgA ̵ ȯڿԴ Ƴʶü (anaphylactic reactions) Ÿ ֽϴ.
3. ļ ȯ (Transfusion-transmitted infections)
õ 鿪, B , C , parvovirus ż ĵ ֽϴ. п ĵǴ Herpes ̷, Ŵ뼼̷ (CMV), ʽϴ. ż忡 ֺ̽ (graft-versus-host disease) Ͽٴ Ƿ 缱 ʿմϴ.
4.
ABO- ż -A -B ü ȯ ֽϴ.
5. ջ (Transfusion-related acute lung injury, TRALI)
ſ 幰 Ǵ ż峻 ȯ ü Ǿ (leukocyte aggregates) Ǿ ջ ߵ ֽϴ.
6. 鿪
ֱ ż 鿪 ȿ ʷ ִٴ ֽϴ.
ż ùٸ Դϴ. ż ϸ B C , AIDS ļ ȯ ȸ Ǵ ˺ι, 鿪۷κҸ ȹ ᰡ Ǵ ڿ ʷ Ƿ , 汸 ȿ ż , ̻ ݵ DIC, ǰҼ ڹ Ǵ ݵ ȯ ùٸ Ǵ 쿡 ϵ ϴ ǰ ֽϴ.
.ħ(Cryoprecipitates) Դϱ?
ħ ż 1 4C 쿩 Դϴ. ħ(cold precipitated protein) factor VIII:C, von Willebrand factor, fibrinogen, factor XIII fibronectin Ǿ ֽϴ. ̰ иϿ -18C Ͽ ħԴϴ. Ⱓ 1Դϴ. ħ Ǿ ִ ħ ܹ ټ ̰ µ factor VIII:C 80-120 , fibrinogen 250 mg, von Willebrand factor ó 忡 40-70%, Factor XIII 20-30% ˴ϴ.
쿡 ˴ϱ?
ħ 캴 A, von Willebrand , õ Ȥ õ fibrinogen , Factor XIII պ Ǵ fibrinogen Ҹ ȯ ˴ϴ.
Դϱ?
ABO ħ 뷮 anti-A anti-B ҿ ߵ Ƿ ABO ħ ؾ մϴ. ̳ õ鿪 ų ֽϴ. ħ 뷮 ϸ ȯ fibrinogen ũ ö hyperfibrinogenemia ߽ (thromboembolism) ʷ Ƿ 뷮 Խ ؾ մϴ.
ؾ մϱ?
ϱ ħ 37C Դϴ. 鿡 쿡 ӿ ִ factor VIII Ǵ fibrinogen ִ ȸϱ ؼ ҷ Ŀ ų մϴ. ݵ Ʈ ؾ մϴ. ħ 6ð ֽϴ. 뷮 մϴ.
差(mL) = x (1-츶ũƮ)
Ǵ 츶ũƮ 40 mL/kg x ü(kg)
Factor VIII units = 差 x (ǥ% - % factor VIII)
ħ ʿ䷮(bags) = Factor VIII units/80 (units/bag)
. ä (Apheresis Granulocytes) Դϱ?
ä (leukapheresis) ̿Ͽ ڷκ մϴ. ı, ԵǾ 差 200-250 mL ˴ϴ. ä ¿Ǹ ä 1 x 1010 ̻ Ǿ ġȿ ֽϴ. ؼ ä 12ð ڿ steroid Ǵ G-CSF Ͽ մϴ. G-CSF 5-10 /kg ( 밳 300 ) (subcutaneous) ֻմϴ. G-CSF ֻ ̿ Ƿΰ ֽϴ. 20-24C Ͽ ϸ ʾ 24ð ̳ ؾ մϴ.
쿡 ˴ϱ?
شǴ ȯڿ ˴ϴ.
1. (myeloid hypoplasia)
2. ȣ߱ (<500/l)
3. ġῡ ȣ ߿ 24-48 ð ӵɶ, Ǵ
ġῡ ϴ
4. ȸ ִ ȯ
Ÿ Ҿȯ ֽϴ.
Դϱ?
ȸ ǽɽ 쿡 δ ȣ߱ ȯ ӻ ȣų ϴ. , ߿ μ ߽ų ֽϴ. ӵ õõ ϰ diphenhydramine̳ meperidine ϸ ۿ ֽϴ. ̵ ƽǸ ̿ ؿ ߿ ġϰų ϴµ ֽϴ. ߿ Ͼų ջ (transfusion-associated acute lung injury) Ͼ ϴ ϴ. , õ 鿪 cytomegolovirus ļ ȯ ʷ 輺 HLA 鿪 ֽϴ. 鿪 ȯ Ǵ 鿪 Ǿ ִ ȯڿ ϸ ̽ȯ(GVHD) ų Ƿ 쿡 缱 縦 ؾ մϴ. 2500 cGy 缱 縦 GVHD ִ װ Ͽ ֽϴ. ״ٴ , amphotericin ÿ ϸ 輺 Ѵٴ ֽϴ.
ؾ մϱ?
κ HLA typing ԵǾ Ƿ ݵ Ͽ մϴ. 뷮̳ Ⱓ ؼ Ϲ Ǵ 1 x 1010 ̻ 4 ̻ Ͽ ȿ ִ ǰ ֽϴ. ݵ ǥͰ ִ Ʈ Ͽ մϴ.
.缱 (Irradiated Blood Components)
缱 Դϱ?
Ұϰ ȥԵǾ ֽϴ. 109, 108-109, ǿ 107-108, äǿ 106-108 Ǵ Ǿ ֽϴ. (CD8+ T cells) ִ ä ȯڿ Ǹ, Ư 鿪 ϵǾ ִ ȯ (̽ Ǵ ̽ ȯ, 缱 ġ Ǵ ġḦ ȯ) Ǹ ȯ ȿ Ͽ ȯ Ǽ ϴ ֺ̽ (Graft-Versus-Host Disease, GVHD) ߵ ֽϴ.
ֺ̽ (Graft-Versus-Host Disease, GVHD)̶?
ֺ̽ ִ ߵǸ Ǻι, ߿, , Ȳ, Ÿ ֽϴ. ſ ݵ Ǿ մϴ. GVHD ϱ ؼ ȥԵǾ ִ ִ մϴ. ͷ ص Ű Ͽ ȿ ϴ. GVHD ؼ ݵ 缱⸦ ̿Ͽ 缱 Ͽ մϴ.
鿪 ȯڿԵ GVHD ߵ ֽϴ. Ư HLA ȯ HLA haplotype ϳ homozygote (: HLA type A2/A2̰ ȯ HLA type A2/A24 ) GVHD ɼ ϴ. ֳϸ ׳ ϴ HLA A2/A2 ִ ȯ ӿ Ǹ ȯڿԴ HLA A2 ڽŰ Ƿ ȯ ӿ HLA A24 ٸ Ǿ ϰ ̸ ֱ Դϴ. ̷ 찡 ֱ Ǹ ְ 쿡 ݵ 缱 縦 Ͽ մϴ.
缱
شϴ 쿡 ݵ 缱 Ͽ մϴ.
1) ̽ (Allogeneic and autologous bone marrow transplantation)
2) õ 鿪 ı (Congenital immune deficiency syndromes)
3) ȣŲ (Hodgkin's disease)
4) ڱó ¾ (Intrauterine exchange transfusion)
5) ̼ (Prematurity)
6) 鿪 Ǵ 缱 ġ (Immunosuppressive and/or irradiation therapy)
7) ı (Acute lymphocytic leukemia)
8) (All directed donations)
缱 մϱ?
Ǿ ִ ִ ̱ ؼ 缱⸦ ̿Ͽ 2,500 rad(cGy) 缱() Ͽ մϴ. 쿡 ʰ ֽϴ. δ ݰⰡ 30 Ǵ Cesium-137 մϴ. ſ 缱 簡 ÿ ʿ 쿡 Ÿ ϴ ϴٴ ֽϴ.
缱縦 ؾ dz?
ϴ. ä ̿ Ƿ żԴϴ. κ Ƿ GVHD ߽ų ɼ ϴ. ֿ 2,500 rad ʽϴ.
*ó : ߾Ӿƻ꺴 (http://www.amc.seoul.kr/~swkwon/)
|
|